⌘+K

Latest share price

SEK

0.6

3.45%

16 Nov 2026 17:21 CET

Fair value range

SEK

0.2

—

2.0

5 Nov 2026

Market cap

SEK

73

m

Next report

Q4

11 Feb 2027

Ascelia Pharma

Healthcare

2026-11-05

Type A meeting completed, next steps pending - Q3 review

Ascelia’s Q3 report showed continued cost control and reduced cash burn, while key focus remains the regulatory path for Orviglance after the FDA’s Type A meeting....

Post-Results Note

Maria Karlsson Osipova

Type A meeting completed, next steps pending - Q3 review

FDA requests additional clinical evidence

September meeting to define path forward - Q2 review

Ascelia Pharma

Healthcare

2026-10-12

FDA requests additional clinical evidence

Following its Type A meeting with the FDA, Ascelia has received the official meeting minutes, confirming that additional clinical evidence will be required for...

News

Maria Karlsson Osipova

Type A meeting completed, next steps pending - Q3 review

FDA requests additional clinical evidence

September meeting to define path forward - Q2 review

Ascelia Pharma

Healthcare

2026-08-24

September meeting to define path forward - Q2 review

Ascelia’s Q2 report focused primarily on the Orviglance CRL and the regulatory path forward, with management reiterating its strong confidence in the asset. In our view,...

Post-Results Note

Maria Karlsson Osipova

Type A meeting completed, next steps pending - Q3 review

FDA requests additional clinical evidence

September meeting to define path forward - Q2 review

Price chart

Price

Fair range high value

Fair range low value

Year

2024

2025

2026e

2027e

2028e

EPS

-1.21

-0.68

-0.34

-0.07

-0.07

EPS (Adj.)

-1.21

-0.68

-0.34

-0.07

-0.07

Sales Growth

-62.55%

-66.36%

157.58%

EPS Growth (Adj.)

-75.99%

P/E

P/E (Adj.)

EV/EBITA

-0.3

-0.3

-1.3

-5.8

-6.8

EV/EBITDA

-0.3

-0.3

-1.3

-5.8

-6.8

Learn more

Key facts

Sector

Healthcare

Country

Sweden

Tickers

ACE@SS, ACE.ST

CEO

Magnus Corfitzen

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB